Collegium Strikes $650M Deal for AZSTARYS, Expects Immediate Accretion and $50M H2 2026 Revenue
summarizeSummary
Collegium Pharmaceutical announced a definitive agreement to acquire AZSTARYS from Corium Therapeutics for $650 million in cash, with potential additional milestone payments up to $135 million. This highly material acquisition, funded by existing cash and a previously announced $300 million delayed draw term loan, significantly expands Collegium's ADHD portfolio. AZSTARYS is expected to generate over $50 million in pro forma net revenue in the second half of 2026 and extends patent protection into 2037. The transaction is anticipated to be immediately accretive to adjusted EBITDA, strengthening the company's financial position and accelerating its growth trajectory. Investors will closely monitor the integration of AZSTARYS and its contribution to Collegium's revenue and profitability targets.
At the time of this announcement, COLL was trading at $34.80 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.1B. The 52-week trading range was $23.23 to $50.79. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.